Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and to demonstrate the repeatability and reproducibility of the AC2 Assay on the PANTHER System.
| Condition | Intervention |
|---|---|
|
Chlamydia Trachomatis Neisseria Gonorrhoeae Infection |
Device: APTIMA COMBO 2 Assay (AC2 Assay) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Clinical Evaluation of the APTIMA® COMBO 2®Assay Using the PANTHER™ System |
- Positive and Negative Percent Agreement Using the TIGRIS Instrument as a Reference [ Time Frame: approximately 1 year ] [ Designated as safety issue: No ]
- APTIMA Combo 2 Assay Accuracy Compared to Infected Status by Sample Type [ Time Frame: Baseline ] [ Designated as safety issue: No ]Count of participants having a positive or negative APTIMA Combo 2 assay result (sensitivity and specificity).
Biospecimen Retention: Samples With DNA
4 specimens will be collected from each female subject in the following order: 1 first-catch urine specimen, 1 vaginal swab specimen (patient or clinician-collected), 1 cervical specimen (using a broomlike collection device or a brush/spatula combination), and 1 endocervical swab specimen. An additional cervical specimen may be collected from female subjects for other clinical trial purposes or research studies. Up to 2 specimens will be collected from each male subject in the following order: 1 urethral swab specimen and 1 first-catch urine specimen
| Enrollment: | 1947 |
| Study Start Date: | November 2010 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| No treatment |
Device: APTIMA COMBO 2 Assay (AC2 Assay)
APTIMA COMBO 2 Assay (AC2 Assay
|
Detailed Description:
The results of this protocol AC2PS-US11-001 (NCT01733069) are based on samples collected from protocol ACTPS-US10-001(NCT01358799).
The registration for NCT01358799 was withdrawn because the samples were not tested under protocol ACTPS-US10-001, instead they were tested under the protocol registered here AC2PS-US11-001 (NCT01733069).
Eligibility| Ages Eligible for Study: | 14 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Male and Females at least 14 years of age at the time of informed consent and sexually active.
Inclusion Criteria:
•The subject is at least 14 years of age at the time of informed consent and is sexually active
- The subject reports symptoms consistent with a suspected STD (sexually transmitted disease) such as abnormal discharge, genital itching, pain/discomfort during sexual intercourse or urination, and/or lower abdominal discomfort.
- If the subject is asymptomatic, the subject is known to be partners with, or a contact of, a person with a confirmed or suspected STD(s), is undergoing screening evaluation for a possible STD(s), and/or is scheduled for a routine exam that may include a pelvic exam
- The subject and/or legally authorized representative is willing to undergo the informed consent process prior to study participation (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an IRBapproved waiver for parental consent for minors)
Exclusion Criteria:
•A potential subject will be ineligible for clinical trial enrollment if the subject, clinician, or medical record reports any of the following:
- The subject took antibiotic medications within the last 21 days
- The subject is underage (as defined by the IRB (institutional review board) or state law), without the documented consent of her/his parent or legal guardian (exception: sites that have an IRBapproved waiver for parental consent for minors)
- The subject is determined by the investigator to be medically unsuitable for participation in this study (eg, medical history of concurrent illness that could result in an unacceptable risk to the subject) Concurrent participation in other clinical study(ies) may be acceptable, with approval by the investigator and sponsor.
Contacts and Locations| United States, Indiana | |
| Wishard Health Services Department of Pathology Wishard Health Services | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Louisiana | |
| Louisiana State University Health Center | |
| New Orleans, Louisiana, United States, 70122 | |
| United States, Massachusetts | |
| New England Center for Clinical Research | |
| Fall River, Massachusetts, United States, 02720 | |
| United States, North Carolina | |
| University of North Carolina Chapel Hill STD Clinic | |
| Chapel Hill, North Carolina, United States, 27599 | |
| United States, Ohio | |
| Planned Parenthood Northeast Ohio | |
| Akron, Ohio, United States, 44302 | |
| Cincinnati Children's Hospital Medical Center Division of Pediatric & Adolescent Gynecology | |
| Cincinnati, Ohio, United States, 45229 | |
| United States, Texas | |
| Planned Parenthood Houston and Southeast Texas | |
| Houston, Texas, United States, 77023 | |
| Study Director: | Jennifer Reid, PhD | Gen-Probe, Incorporated |
More Information
No publications provided
| Responsible Party: | Gen-Probe, Incorporated |
| ClinicalTrials.gov Identifier: | NCT01733069 History of Changes |
| Other Study ID Numbers: | AC2PS-US11-001, ACTPS-US10-001 |
| Study First Received: | November 20, 2012 |
| Results First Received: | March 7, 2013 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Chlamydia Infections Gonorrhea Chlamydiaceae Infections Gram-Negative Bacterial Infections Bacterial Infections Sexually Transmitted Diseases, Bacterial |
Sexually Transmitted Diseases Infection Genital Diseases, Male Genital Diseases, Female Neisseriaceae Infections |
ClinicalTrials.gov processed this record on May 22, 2013